Evidence map›Paper›PMID 34354362›Full record

ArticleJournal of asthma and allergy2021

Characteristics of Reliever Inhaler Users and Asthma Control: A Cross-Sectional Multicenter Study in Portuguese Community Pharmacies.

Mariana Romão, Ana Rita Godinho, Pedro M Teixeira, Zilda Mendes, Filipa Bernardo, António Teixeira Rodrigues, Jaime Correia de Sousa

Open access · goldAbstract read
In one paragraph

Article in Journal of asthma and allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Over-the-counter use of short-acting beta-2 agonists: a systematic review.Journal of pharmaceutical policy and practice · 2023
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mariana RomãoCentre for Health Evaluation & Research/Infosaude - National Association of Pharmacies (CEFAR/IS-ANF), Lisbon, Portugal.ORCID 0000-0001-6437-0631
Ana Rita GodinhoCentre for Health Evaluation & Research/Infosaude - National Association of Pharmacies (CEFAR/IS-ANF), Lisbon, Portugal.
Pedro M TeixeiraLife and Health Sciences Research Institute (ICVS)/3B's-PT Government Associate Laboratory, University of Minho, Braga, Portugal.ORCID 0000-0001-6322-4923
Zilda MendesCentre for Health Evaluation & Research/Infosaude - National Association of Pharmacies (CEFAR/IS-ANF), Lisbon, Portugal.
Filipa BernardoAstraZeneca, Queluz, Lisboa, Portugal.
António Teixeira RodriguesCentre for Health Evaluation & Research/Infosaude - National Association of Pharmacies (CEFAR/IS-ANF), Lisbon, Portugal.ORCID 0000-0002-8161-9264
Jaime Correia de SousaLife and Health Sciences Research Institute (ICVS)/3B's-PT Government Associate Laboratory, University of Minho, Braga, Portugal.ORCID 0000-0001-6459-7908
Associacao Protectora dos Diabeticos de Portugal · PTUniversity of Minho · PTAstraZeneca (Portugal) · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSABA overuse might indicate poorly managed or uncontrolled asthma and be responsible for poor health outcomes. The aim of this study integrated in new fourth multi-design SABINA+ pillar was to characterize the population using short-acting β PATIENTS AND

methodsThis cross-sectional multicenter study was conducted in Portuguese community pharmacies between 29 May 2018 and 15 August 2018. Participants were adults (age ≥18 years) self-reporting asthma diagnosis recruited in the context of a short-acting β

resultsAround 50.8% of patients were male, and the average age was 52 years old. Half of the patients never smoked, and 51.9% were employed. More than half of the patients report inhaler overreliance - purchasing more than 1 pack in 3 months (65.0%) or using the inhaler on more than 8 days over the previous 4 weeks (50.2%). Of the total number of patients in the study, 79.1% had poorly controlled asthma symptoms, and 78.7% had overall poorly controlled respiratory symptoms. We found statistically significant differences between GINA treatment steps in all sociodemographic characteristics (sex, mean age, education level, employment status); maximum number of SABA uses in 24h, CARAT score (total an asthma sub-score); history of exacerbations requiring ED visits or treatment with OCS for at least 3 days in the previous 12 months. Logistic regression revealed that patients reporting SABA use in more than 8 days in the previous 4 weeks and patients with at least 1 exacerbation requiring treatment with OCS for at least 3 days in the previous 12 months have greater odds of poor disease control [adjusted OR (95% CI): 2.6 (1.3-5.2) and 3.0 (1.3-6.6)].

conclusionBased on the results of this study, it can be inferred that the asthma population using SABA is largely uncontrolled and uses reliever inhalers excessively.

Indexed as

CARAT®chronic diseaseexacerbationsoveruseshort-acting beta-2 adrenergic agonist

Identifiers

PMID34354362
PMCPMC8331120
OpenAlexW3188542948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.